Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Provided By GlobeNewswire
Last update: May 5, 2025
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production -
- Findings offer a more detailed understanding of WTX-921’s anti-inflammatory impact on the immune landscape in the inflamed colon -
Read more at globenewswire.com1.21
-0.07 (-5.47%)
Find more stocks in the Stock Screener
HOWL Latest News and Analysis
10 days ago - ChartmillTop movers in Tuesday's after hours sessionAs the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
